Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence

Pediatric Pulmonology

Volumn 49, Issue 5, 2014, Pages 503-507

  Tanou, Kalliopi ^a   Zintzaras, Elias ^b,c   Kaditis, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

A. fumigatus; ABPA; anti IgE

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; ITRACONAZOLE; METHYLPREDNISOLONE; OMALIZUMAB; PREDNISONE; VORICONAZOLE; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DATA SYNTHESIS; FORCED EXPIRATORY VOLUME; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHILD; COMPLICATION; FEMALE; MALE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 84898600933     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22937     Document Type: Article

References (13)

1. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G,. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: S225-S264.
2. van der Ent CK, Hoekstra H, Rijkers GT,. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62: 276-277.
3. Zirbes JM, Milla CE,. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43: 607-610.
4. Kanu A, Patel K,. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43: 1249-1251.
5. Lebecque P, Leonard A, Argaz M, Godding V, Pilette C,. Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep 2009; 2009:bcr07.2008.0379.
6. Randhawa I, Chin T, Nussbaum E,. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 2009; 46: 445-447.
7. Brinkmann F, Schwerk N, Hansen G, Ballmann M,. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010; 65: 134-135.
8. Elmallah MK, Hendeles L, Hamilton RG, Capen C, Schuler PM,. Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin E therapy (omalizumab). J Pediatr Pharmacol Therap 2012; 17: 88-92.
9. Wong R, Wong M, Robinson PD, Fitzgerald DA,. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Paediatr Respir Rev 2013; 14: 22-24.
10. Lebecque P, Leonard A, Pilette C,. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009; 44: 516.
11. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB,. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
12. Soresi S, Togias A,. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc 2006; 27: S15-S23.
13. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV,. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-593.